NeoGenomics (NEO) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'
March 2, 2016 2:16 PM ESTBTIG reaffirms its Buy rating and $9 price target on NeoGenomics Inc. (Nasdaq: NEO) following Q4 results and outlook issued yesterday morning.
Analyst Sean Lavin noted that FY16 guidance was largely inline with prior expectations. Commentary around initial integration efforts was encouraging,... More
